Circulating tumor cells, DNA, and mRNA: Potential for clinical utility in patients with melanoma

Oncologist

Volumn 21, Issue 1, 2016, Pages 84-94

  Xu, Melody J ^a   Dorsey, Jay F ^a   Amaravadi, Ravi ^a   Karakousis, Giorgos ^b   Simone, Charles B ^a   Xu, Xiaowei ^b   Xu, Wei ^a   Carpenter, Erica L ^a   Schuchter, Lynn ^a   Kao, Gary D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Circulating mRNA; Circulating tumor cells; Circulating tumor DNA; Clinical utility; Melanoma

Indexed keywords

ABC TRANSPORTER B5; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD146 ANTIGEN; CIRCULATING TUMOR DNA; COMPLEMENTARY DNA; DNA; K RAS PROTEIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; N ACETYLGALACTOSAMINYLTRANSFERASE; PROTEOCHONDROITIN SULFATE; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG; VEMURAFENIB; TUMOR MARKER;

ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SURVEILLANCE; DNA DETERMINATION; DRUG RESPONSE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; MOLECULAR BIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; BLOOD; GENETICS; PATHOLOGY; PROGNOSIS; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; DNA, NEOPLASM; HUMANS; MELANOMA; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RNA, MESSENGER;

EID: 84954342252     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0207     Document Type: Article

References (98)

1. Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci 2014;51:160-171.
2. Rodic S, Mihalcioiu C, Saleh RR. Detection methods of circulating tumor cells in cutaneous melanoma: A systematic review. Crit Rev Oncol Hematol 2014;91:74-92.
3. Mumford BS, Robertson GP. Circulating melanoma cells in the diagnosis and monitoring of melanoma: An appraisal of clinical potential. Mol Diagn Ther 2014;18:175-183.
4. Medic S, Pearce RL, Heenan PJ et al. Molecular markers of circulating melanoma cells. Pigment Cell Res 2007;20:80-91.
5. Nezos A, Msaouel P, Pissimissis N et al.Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev 2011;37:284-290.
6. Kounalakis N, Goydos JS. Tumor cell and circulating markers in melanoma: Diagnosis, prognosis, and management. Curr Oncol Rep 2005;7: 377-382.
7. Khoja L, Lorigan P, Dive C et al. Circulating tumour cells as tumour biomarkers in melanoma: Detection methods and clinical relevance. Ann Oncol 2015;26:33-39.
8. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
10. Wolchok JD, Hodi FS, Weber JS et al. Development of ipilimumab: A novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013;1291:1-13.
11. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-133.
12. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-723.
13. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl JMed 2013;369:134-144.
14. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl JMed 2011;364: 2507-2516.
15. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Lett 2007;253:180-204.
16. Rao C, Bui T, Connelly M et al. Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol 2011;38:755-760.
17. Klinac D, Gray ES, Freeman JB et al. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer 2014;14:423.
18. Reid AL, Freeman JB, Millward M et al. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin Biochem 2015;48:999-1002.
19. Ruiz C, Li J, Luttgen MS et al. Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol 2015;12:016008.
20. Khoja L, Lorigan P, Zhou C et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol 2013;133: 1582-1590.
21. Kitago M, Koyanagi K, Nakamura T et al. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigenspecific monoclonal antibody beads. Clin Chem 2009;55:757-764.
22. Bidard FC, Madic J, Mariani P et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer 2014;134:1207-1213.
23. VonaG, Sabile A,LouhaMetal. Isolationbysizeof epithelial tumor cells: A new method for the immunomorphological andmolecular characterization of circulating tumor cells.AmJ Pathol 2000;156:57-63.
24. De Giorgi V, Pinzani P, Salvianti F et al. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 2010;130:2440-2447.
25. Khoja L, ShenjereP,HodgsonCet al. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Res 2014;24:40-46.
26. Clawson GA, Kimchi E, Patrick SD et al. Circulating tumor cells in melanoma patients. PLoS One 2012;7:e41052.
27. Xu MJ, Cooke M, Steinmetz D et al. A novel approach for the detection and genetic analysis of live melanoma circulating tumor cells. PLoS One 2015;10:e0123376.
28. Jamal-Hanjani M, Quezada SA, Larkin J et al. Translational implications of tumor heterogeneity. Clin Cancer Res 2015;21:1258-1266.
29. Jamal-Hanjani M, Hackshaw A, Ngai Y et al. Tracking genomic cancer evolution for precision medicine: The lung TRACERx study. PLoS Biol 2014; 12:e1001906.
30. Caixeiro NJ, Kienzle N, Lim SH et al. Circulating tumour cells-a bona fide cause of metastatic cancer. Cancer Metastasis Rev 2014;33:747-756.
31. Baccelli I, Schneeweiss A, Riethdorf S et al. Identification of a population of blood circulating tumorcells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-544.
32. Hodgkinson CL, Morrow CJ, Li Y et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014;20: 897-903.
33. Newman AM, Bratman SV, To J et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-554.
34. Lipson EJ, Velculescu VE, Pritchard TS et al. Circulating tumor DNA analysis as a real-time method formonitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer 2014;2:42.
35. Diaz LA Jr., Bardelli A. Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 2014;32: 579-586.
36. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA 1999;96:9236-9241.
37. Dressman D, Yan H, Traverso G et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 2003; 100:8817-8822.
38. Liu Q, Sommer SS. Pyrophosphorolysisactivated polymerization (PAP): Application to allele-specific amplification. Biotechniques 2000; 29:1072-1076, 1078, 1080 passim.
39. Diehl F, Schmidt K, Choti MA et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-990.
40. Leary RJ, Kinde I, Diehl F et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci TranslMed 2010;2: 20ra14.
41. Leary RJ, Sausen M, Kinde I et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4:162ra154.
42. McBride DJ, Orpana AK, Sotiriou C et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 2010;49: 1062-1069.
43. Campbell PJ, Stephens PJ, Pleasance ED et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 2008; 40:722-729.
44. Bettegowda C, Sausen M, Leary RJ et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
45. Forshew T, Murtaza M, Parkinson C et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68.
46. Sanmamed MF, Fernández-Landázuri S, Rodríguez C et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem 2015;61:297-304.
47. Murtaza M, Dawson SJ, Tsui DW et al. Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasmaDNA. Nature 2013; 497:108-112.
48. Pantel K, Diaz LA Jr., Polyak K. Tracking tumor resistance using 'liquid biopsies'. Nat Med 2013;19: 676-677.
49. Kiyohara E, Hata K, Lam S et al. Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients. Methods Mol Biol 2014;1102: 513-522.
50. Mocellin S, Hoon D, Ambrosi A et al. The prognostic value of circulating tumor cells in patients with melanoma: A systematic review and meta-analysis. Clin Cancer Res 2006;12:4605-4613.
51. De Giorgi V, Pinzani P, Salvianti F et al. Circulating benign nevus cells detected by ISET technique: Warning for melanoma molecular diagnosis. Arch Dermatol 2010;146:1120-1124.
52. Smith B, Selby P, Southgate J et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227-1229.
53. Koyanagi K, Kuo C, Nakagawa T et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 2005;51:981-988.
54. Koyanagi K, O'Day SJ, Gonzalez R et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: Outcome prediction in a multicenter trial. J Clin Oncol 2005;23:8057-8064.
55. Koyanagi K, O'Day SJ, Boasberg P et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 2010;16:2402-2408.
56. Hoshimoto S, Faries MB, Morton DL et al. Assessment of prognostic circulatingtumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 2012;255:357-362.
57. Hoshimoto S, Shingai T, Morton DL et al. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 2012; 30:3819-3826.
58. Barry MJ. Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 2009; 360:1351-1354.
59. Karagiannis P, Fittall M, Karagiannis SN. Evaluating biomarkers in melanoma. Front Oncol 2014;4:383.
60. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl JMed 2004;351: 781-791.
61. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14: 6302-6309.
62. Cohen SJ, Punt CJ, IannottiNet al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-3221.
63. Raimondi C, Gradilone A, Naso G et al. Clinical utility of circulating tumor cell counting through CellSearch(®): The dilemma of a concept suspended in Limbo. Onco Targets Ther 2014;7:619-625.
64. Bidard FC, Peeters DJ, Fehm T et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014;15: 406-414.
65. Final Comment and Response. Available at http://downloads.cms.gov/medicare-coveragedatabase/ lcd_attachments/32218_1/ DL32218_PATH033_FinalComments.pdf. Accessed May 19, 2015.
66. Janssen Diagnostics. Reimbursement. 2015. Available at https://www.cellsearchctc.com/ support-resources/reimbursement. Accessed November 9, 2015.
67. Mocellin S, Hoon DS, Pilati P et al. Sentinel lymph node molecular ultrastaging in patients with melanoma: A systematic review and meta-analysis of prognosis. J Clin Oncol 2007;25:1588-1595.
68. Nicholl MB, Elashoff D, Takeuchi H et al. Molecular upstaging based on paraffin-embedded sentinel lymph nodes: Ten-year follow-up confirms prognostic utility in melanoma patients. Ann Surg 2011;253:116-122.
69. Carlson JJ, Roth JA.The impact of theOncotype Dx breast cancer assay in clinical practice: A systematic review and meta-analysis. Breast Cancer Res Treat 2013;141:13-22.
70. Partin JF, Mamounas EP. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptorpositive breast cancer. Ann Surg Oncol 2011;18: 3399-3406.
71. Asad J, Jacobson AF, Estabrook A et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?Am J Surg 2008;196:527-529.
72. Paik S, Shak S,TangGet al.Amultigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004;351: 2817-2826.
73. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
74. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
75. National Cancer Institute. The TAILORx Breast Cancer Trial. Updated September 28, 2015. Available at http://www.cancer.gov/clinicaltrials/ noteworthy-trials/tailorx. Accessed November 9, 2015.
76. Genomic Health. Genomic Health announces year-end 2014 financial results, provides 2015 financial outlook. February 10, 2015. Available at http://www.prnewswire.com/news-releases/ genomic-health-announces-year-end-2014- financial-results-provides-2015-financial-outlook- 300033988.html. Accessed February 13, 2015.
77. Mori T, O'Day SJ, Umetani N et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005;23:9351-9358.
78. Taback B, O'Day SJ, Boasberg PD et al. Circulating DNA microsatellites: Molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 2004;96:152-156.
79. Bidard FC, Fehm T, Ignatiadis M et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013;32:179-188.
80. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372: 793-795.
81. Shinozaki M, O'Day SJ, KitagoMet al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 2007;13:2068-2074.
82. Fujimoto A, Takeuchi H, Taback B et al. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 2004;64: 2245-2250.
83. Hoon DS, Spugnardi M, Kuo C et al. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004;23:4014-4022.
84. Fujiwara Y, Chi DD, Wang H et al. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res 1999;59:1567-1571.
85. Joshi P, Jacobs B, Derakhshan A et al. Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma. Oncotarget 2014;5:2450-2461.
86. Cayrefourcq L, Mazard T, Joosse S et al. Establishment and characterization of a cell line from humancirculatingcoloncancer cells.CancerRes2015; 75:892-901.
87. Yuan D, Chen L, Li M et al. Isolation and characterization of circulating tumor cells from human gastric cancer patients. J Cancer Res Clin Oncol 2015;141:647-660.
88. Bobek V, Gurlich R, Eliasova P et al. Circulating tumor cells in pancreatic cancer patients: Enrichment and cultivation. World J Gastroenterol 2014; 20:17163-17170.
89. Powell AA,Talasaz AH, ZhangHet al. Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012;7:e33788.
90. Yokobori T, Iinuma H, Shimamura T et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 2013;73:2059-2069.
91. KallergiG,PapadakiMA,PolitakiEetal.Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early andmetastatic breast cancer patients. Breast Cancer Res 2011;13:R59.
92. Balasubramanian P, Lang JC, Jatana KR et al. Multiparameter analysis, includingEMTmarkers,on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PLoS One 2012;7:e42048.
93. Hou JM, Krebs MG, Lancashire L et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-532.
94. Duda DG, Duyverman AM, Kohno M et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci USA 2010;107: 21677-21682.
95. MacArthur KM, Kao GD, Chandrasekaran S et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res 2014;74:2152-2159.
96. Dorsey JF, Kao GD, MacArthur KM et al. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results. Cancer 2015;121: 139-149.
97. Ju M, Kao GD, Steinmetz D et al. Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study. Cancer Biol Ther 2014;15:683-687.
98. Hoon DS, Bostick P, Kuo C et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000;60: 2253-2257.